FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Drug testing and analysis2021; 14(2); 349-370; doi: 10.1002/dta.3189

Identification of equine in vitro metabolites of seven non-steroidal selective androgen receptor modulators for doping control purposes.

Abstract: Selective androgen receptor modulators, SARMs, are a large class of compounds developed to provide therapeutic anabolic effects with minimal androgenic side effects. A wide range of these compounds are available to purchase online and thus provide the potential for abuse in sports. Knowledge of the metabolism of these compounds is essential to aid their detection in doping control samples. In vitro models allow a quick, cost-effective response where administration studies are yet to be carried out. In this study, the equine phase I metabolism of the non-steroidal SARMs GSK2881078, LGD-2226, LGD-3303, PF-06260414, ACP-105, RAD-140 and S-23 was investigated using equine liver microsomes. Liquid chromatography coupled to a QExactive Orbitrap mass spectrometer allowed identification of metabolites with high resolution and mass accuracy. Three metabolites were identified for both GSK2881078 and LGD-2226, four for LGD-3303 and RAD-140, five for PF-06260414, twelve for ACP-105 and ten for S-23. The equine metabolism of GSK-2881078, LGD-2226, LGD-3303 and PF-06260414 is reported for the first time. Although the equine metabolism of ACP-105, RAD-140 and S-23 has previously been reported, the results obtained in this study have been compared with published data.
© 2021 John Wiley & Sons, Ltd.
Get Full Text
Publication Date: 2021-12-10 PubMed ID: 34714606DOI: 10.1002/dta.3189Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article discusses the identification of how horses metabolise non-steroidal selective androgen receptor modulators (SARMs), focusing on seven specific ones. These findings are crucial for detecting their misuse in horseracing and other horse sports.

Objective of the Research

  • The main aim of the study was to understand the metabolism of non-steroidal selective androgen receptor modulators (SARMs) in horses. This is particularly important since these substances can be abused in horse sports to improve performance.
  • A secondary goal was to provide foundations for adequate doping controls in sports involving horses. By understanding the metabolic process, the researchers hope to improve detection methods for these drugs in equine doping control samples.

Selective Androgen Receptor Modulators (SARMs)

  • SARMs are a class of drugs designed to provide therapeutic anabolic effects (those involving the building up of tissues), while minimising the androgenic side effects (those related to male hormone activity).
  • A variety of these compounds can be easily purchased online, increasing the potential for misuse in sports like horseracing.

Approach and Methodology

  • The researchers examined the phase I metabolism processes of seven non-steroidal SARMs by using in vitro models, specifically equine liver microsomes. This was a more time- and cost-effective approach compared to immediately conducting administration studies.
  • The SARMs studied were GSK2881078, LGD-2226, LGD-3303, PF-06260414, ACP-105, RAD-140, and S-23.
  • A combination of liquid chromatography and a QExactive Orbitrap mass spectrometer was used to identify the metabolites of these drugs. This setup provided high resolution and accurate measurement of mass.

Findings

  • Three metabolites each were identified for GSK2881078 and LGD-2226, four each for LGD-3303 and RAD-140, five for PF-06260414, twelve for ACP-105, and ten for S-23.
  • This was the first time the metabolism of GSK-2881078, LGD-2226, LGD-3303, and PF-06260414 was reported in horses.
  • Although the equine metabolism of ACP-105, RAD-140, and S-23 had been reported before, the study’s results were compared with the previously collected data.

Cite This Article

APA
Cutler C, Viljanto M, Taylor P, Hincks P, Biddle S, Van Eenoo P. (2021). Identification of equine in vitro metabolites of seven non-steroidal selective androgen receptor modulators for doping control purposes. Drug Test Anal, 14(2), 349-370. https://doi.org/10.1002/dta.3189

Publication

Drug testing and analysis
ISSN: 1942-7611
NlmUniqueID: 101483449
Country: England
Language: English
Volume: 14
Issue: 2
Pages: 349-370

Researcher Affiliations

Cutler, Charlotte
  • LGC Ltd, Fordham, UK.
  • Doping Control Laboratory, Ghent University (UGent), Ghent, Belgium.
Viljanto, Marjaana
  • LGC Ltd, Fordham, UK.
Taylor, Polly
  • LGC Ltd, Fordham, UK.
Hincks, Pamela
  • LGC Ltd, Fordham, UK.
Biddle, Simon
  • LGC Ltd, Fordham, UK.
Van Eenoo, Peter
  • Doping Control Laboratory, Ghent University (UGent), Ghent, Belgium.

MeSH Terms

  • Anabolic Agents / metabolism
  • Androgens / analysis
  • Animals
  • Chromatography, Liquid / methods
  • Doping in Sports
  • Horses
  • Receptors, Androgen / metabolism
  • Substance Abuse Detection / methods
  • Substance Abuse Detection / veterinary

References

This article includes 45 references
  1. Negro-Vilar A. Selective androgen receptor modulators (SARMs): A novel approach to androgen therapy for the new millennium.. J Clin Endocrinol Metab 1999;84(10):3459-3462.
  2. International Federation of Horseracing Authorities. International agreement on breeding, racing and wagering. 2021. Accessed 02 August 2021. https://www.ifhaonline.org/resources/ifAgreement.pdf
  3. World Anti-Doping Agency. The 2021 prohibited list international standard. 2021. Accessed 02 August 2021. https://www.wada-ama.org/sites/default/files/resources/files/2021list_en.pdf
  4. Grata E, Perrenoud L, Saugy M, Baume N. SARM-S4 and metabolites detection in sports drug testing: a case report.. Forensic Sci Int 2011;213(1-3):104-108.
  5. Starcevic B, Ahrens BD, Butch AW. Detection of the selective androgen receptor modulator S-4 (Andarine) in a doping control sample.. Drug Test Anal 2013;5(5):377-379.
  6. Cox HD, Eichner D. Detection of LGD-4033 and its metabolites in athlete urine samples.. Drug Test Anal 2017;9(1):127-134.
  7. Cawley AT, Smart C, Greer C, Liu Lau M, Keledjian J. Detection of the selective androgen receptor modulator andarine (S-4) in a routine equine blood doping control sample.. Drug Test Anal 2016;8(2):257-261.
  8. Scarth J, Bailly-Chouriberry L, Sams R. Analytical advances in horseracing medication and doping control.. Proceedings of the 21st International Conference of Racing Analysts and Veterinarians Uruguay, 2016.
  9. Scarth J, McKinney A, Bailly-Chouriberry L. Analytical advances in horseracing medication and doping control from 2016 to 2018.. Proceedings of the 22nd International Conference of Racing Analysts and Veterinarians Dubai; 2018.
  10. Thevis M, Kohler M, Maurer J, Schlӧrer N, Kamber M, Schänzer W. Screening for 2-quinolone-derived selective androgen receptor agonists in doping control analysis.. Rapid Commun Mass Spectrom 2007;21(21):3477-3486.
  11. Thevis M, Schänzer W. Mass spectrometry of selective androgen receptor modulators.. J Mass Spectrom 2008;43(7):865-876.
  12. Thevis M, Piper T, Beuck S, Geyer H, Schänzer W. Expanding sports drug testing assays: Mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACP-105.. Rapid Commun Mass Spectrom 2013;27(11):1173-1182.
  13. Thevis M, Lagojda A, Kuehne D. Characterization of a non-approved selective androgen receptor modulator drug candidate sold via the Internet and identification of in vitro generated phase-I metabolites for human sports drug testing.. Rapid Commun Mass Spectrom 2015;29(11):991-999.
  14. Thevis M, Volmer DA. Mass spectrometric studies on selective androgen receptor medoulators (SARMs) using electron ionization and electrospray ionization/collision-induced dissociation.. Eur J of Mass Spectrom 2018;24(1):145-156.
  15. Ventura E, Gadaj A, Monteith G. Development and validation of a semi-quantitative ultra-high performance liquid chromatography-tandem mass spectrometry method for screening of selective androgen receptor modulators in urine.. J Chromatogr A 2019;1600:183-196.
    doi: 10.1016/j.chroma.2019.04.050google scholar: lookup
  16. Ventura E, Gadaj A, Buckley T, Mooney MH. Development of a multi-residue high-throughput UHPLC-MS/MS method for routine monitoring of SARM compounds in equine and bovine blood.. Drug Test Anal 2020;12(9):1373-1379.
    doi: 10.1002/dta.2875google scholar: lookup
  17. Ventura E, Gadaj A, Buckley T, Mooney MH. Investigation of stability of selective androgen receptor modulators in urine.. Food Additive Contaminants: Part A 37(8):1253-1263.
  18. International Laboratory Accreditation Cooperation. G7: accreditation requirements and operating criteria for horseracing laboratories. https://ilac.org/publications-and-resources/ilac-guidance-series/
  19. Fragakaki AG, Sakellariou P, Kiousi P. Human in vivo metabolism study of LGD-4033.. Drug Test Anal 2018;10(11-12):1635-1645.
  20. Sobolevsky T, Dikunets M, Rodchenkov G. In vitro and in vivo metabolism of RAD140, a novel non-steroidal SARM.. 31st Cologne Workshop on Dope Analysis Manfred-Donike Institute, Cologne, Germany; 2013.
  21. Knoop A, Krug O, Vincenti M, Schänzer W, Thevis M. In vitro metabolism studies on the selective androgen receptor modulator LG121071 and its implementation into human doping controls using liquid chromatography-mass spectrometry.. Eur J Mass Spectrom 2015;21(1):27-36.
  22. Thevis M, Gerace E, Thomas A. Characterization of in vitro generated metabolites of the selective androgen receptor modulators S-22 and S-23 and in vivo comparison to post-administration canine urine specimens.. Drug Test Anal 2010;2(11-12):589-598.
  23. Krug O, Thomas A, Beuck B. Characterization of in vitro synthesized equine metabolites of the selective androgen receptor modulators S24 and S4.. J Equine Vet 2012;32(9):562-568.
  24. Hansson A, Knych H, Stanley S, Thevis M, Bondesson U, Hedeland M. Characterisation of equine urinary metabolites of selective androgen receptor modulators (SARMs) S1, S4 and S22 for doping control purposes.. Drug Test Anal 2015;7(8):673-683.
  25. Hansson A, Knych H, Stanley S, Thevis M, Bondesson U, Hedeland M. Investigation of the selective androgen receptor modulators S1, S4 and S22 and their metabolites in equine plasma using high-resolution mass spectrometry.. Rapid Commun Mass Spectrom 2016;30(7):833-842.
  26. Hansson A, Knych H, Stanley S. Equine in vivo-derived metabolites of SARM LGD-4033 and comparison with human and fungal metabolites.. J Chromatogr B 2018;1074-1075:91-98.
  27. Cutler C, Viljanto M, Hincks P, Habershon-Butcher J, Muir T, Biddle S. Investigation of the metabolism of the selective androgen receptor modulator LGD-4033 in equine urine, plasma and hair following oral administration.. Drug Test Anal 2020;12(2):247-260.
  28. So Y, Wong JKY, Choi TLS. Metabolic studies of the selective androgen receptor modulators RAD-140 and S-23 in horses.. Drug Test Anal 2021;13(2):318-337.
  29. Subhahar MB, Karakka Kal AK, Philip M. Detection and identification of ACP-105 and its metabolites in equine urine using LC/MS/MS after oral administration.. Drug Test Anal 2021;13(2):299-317.
  30. Cutler C, Viljanto M, Taylor P. Equine metabolism of the selective androgen receptor modulator AC-262536 in vitro and in urine, plasma and hair following oral administration.. Drug Test Anal 2021;13(2):369-385.
  31. Broberg MN, Knych H, Bondesson U. Investigation of equine in vivo and in vitro derived metabolites of selective androgen receptor modulator (SARM) ACP-105 for improved doping control.. Metabolites 2021;11(2):85.
    doi: 10.3390/metabo11020085google scholar: lookup
  32. Clark RV, Walker AC, Andrews S, Turnbull P, Wald JA, Magee MH. Safety, pharmacokinetics and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women.. Br J Clin Phamacol 2017;83(10):2179-2194.
  33. Neil D, Clark RV, Magee M. GSK2881078, a SARM, produces dose-dependent increases in lean mass in healthy older men and women.. J Clin Endocrinol Metab 2018;103(9):3215-3224.
  34. Rading A, Anielski P, Thieme D, Keiler AM. Detection of the selective androgen receptor modulator GSK2881078 and metabolites in human urine and hair after a single oral administration.. Drug Test Anal 2021;13(1):217-222.
  35. Gao W, Dalton JT. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs).. Drug Discov Today 2007;12(5-6):241-248.
  36. Rosen J, Negro-Vilar A. Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile.. J Musculoskelet Neuronal Interact 2002;2(3):222-224.
  37. Fonesca GWPD, Dworatzek E, Ebner N, Von Haehling S. Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials.. Expert Opin Investig Drugs 2020;29(8):881-891.
  38. Vajda EG, Lopez FJ, Rix P. Pharmocokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator.. J Pharmacol Exp Ther 2009;328(2):663-670.
  39. Bhattacharya I, Tarabar S, Liang Y, Pradhan V, Owens J, Oemar B. Safety, pharmacokinetic, and pharmacodynamic evaluation after single and multiple ascending doses of a novel selective androgen receptor modulator in healthy subjects.. Clin Ther 2016;38(6):1401-1416.
  40. Schlienger N, Lund BW, Pawlas J. Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators.. J Med Chem 2009;52(22):7186-7191.
  41. Miller CP, Shomali M, Lyttle CR. Design, synthesis, and preclinical characterization of the selective androgen receptor modulator (SARM) RAD140.. ACS Med Chem Lett 2011;2(2):124-129.
  42. Jones A, Chen J, Hwang DJ, Miller DD, Dalton JT. Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception.. Endocrinology 2009;150(1):385-395.
  43. Thevis M, Thomas A, Piper T, Krug O, Delahaut P, Schänzer W. Liquid chromatography-high resolution/high accuracy (tandem) mass spectrometry-based idenitifaction of in vivo generated metabolites of the selective androgen receptor modulator ACP-105 for doping control purposes.. Eur J Mass Spectrom 2014;20(1):73-83.
  44. World Anti-Doping Agency. Technical Letter TL07 (Andarine-Flutamide). 2020. Accessed 21 April 2021. https://www.wada-ama.org/sites/default/files/resources/files/tl07_andarine-flutamide_eng_2021_1.pdf
  45. World Anti-Doping Agency. Technical Letter TL12 (Enobosarm). 2020. Accessed 21 April 2021. https://www.wada-ama.org/sites/default/files/resources/files/tl12_enobosarm_eng_2021.pdf

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,928 horse owners like you who receive our email updates on horse health and nutrition.